Patient Center

Investigational Medicine

Conatus Pharmaceuticals medicine, emricasan (IDN-6556), is considered investigational, meaning that it is being evaluated in clinical trials and are not yet approved for use by regulatory authorities. Approval by regulatory authorities around the world, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), is the means to make our medicines available to the patient.

How to Access Conatus’ Emricasan

To learn more about Conatus’ current clinical programs, you can read our Clinical Development section and visit www.clinicaltrials.gov.

Trials Currently Recruiting

A Placebo-Controlled, Multicenter, Double-Blind, Randomized, Pharmacokinetic and Pharmacodynamic Trial of IDN-6556 in Subjects with Acute-on-Chronic Liver Failure

Study of IDN-6556 in Patients with Severe AH and Contradictions to Steroid Therapy

Caspase Inhibition in Islet Transplantation